Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder CancerIan M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|The Journal of Urology|2022Cited by 71
Reply by AuthorsIan M. McElree, Vignesh T. Packiam, Jordan Richards et al.|The Journal of Urology|2022Cited by 1
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.Phani T. Chevuru, Vignesh T. Packiam, Ian M. McElree et al.|Journal of Clinical Oncology|2022Cited by 0
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|Journal of Clinical Oncology|2022Cited by 0
AN ARTIFICIAL INTELLIGENCE-POWERED MODEL TO PREDICT RESPONSE TO INTRAVESICAL BCG VERSUS GEMCITABINE-DOCETAXEL FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCERVignesh T. Packiam, Michael J. O’Donnell, Ian M. McElree et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 0